Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
The initiative was announced at World Hypertension Congress, Chennai
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Akums invested Rs. 272 crore in capital expenditure during FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Subscribe To Our Newsletter & Stay Updated
